
Licensed to fill prescriptions for patients in RI, MA, CT, NJ, NH, FL, ME and PA. New York patients are served on a limited basis while nonresident registration is pending.
Prepared to a prescriber's order for one patient. Not FDA-approved.
This is a compounded oral liquid containing albendazole, prepared to a prescriber's order for one patient. Compounded preparations are not FDA-approved.
These listings cover every salt or ester form of each drug in the FDA National Drug Code Directory.
FDA-approved products containing albendazole are listed in tablet form. No finished albendazole product of any kind is listed in liquid form.
Liquid bases can be aqueous or nonaqueous, and USP <795> classifies the preparation by its water activity. Aqueous preparations carry shorter default beyond-use dates than nonaqueous ones. The date printed on the label is the one to follow.
Compounded drugs are not FDA-approved. This means that FDA does not review these drugs to evaluate their safety, effectiveness, or quality before they reach patients.
Albendazole is a benzimidazole antiparasitic (anthelmintic) that compounding pharmacies prepare as oral suspensions and capsules.
Albendazole is a synthetic benzimidazole anthelmintic. After an oral dose it is rapidly converted in the liver to albendazole sulfoxide, the active metabolite, which binds beta-tubulin in parasite cells and stops microtubules from forming; the parasite loses its glucose supply, becomes immobile and dies. The manufactured product is a film-coated tablet, Albenza (Amneal) and its generics, FDA-approved for parenchymal neurocysticercosis caused by larval Taenia solium and for cystic hydatid disease of the liver, lung and peritoneum caused by Echinococcus granulosus. DailyMed lists no FDA-approved albendazole oral liquid for human use. Prescribers may order albendazole compounded as an oral suspension for a patient who cannot swallow tablets, as a capsule in a strength the tablet does not provide, or in a vehicle free of a specific excipient. Compounded albendazole preparations are not FDA-approved and require a prescription.
The Albenza label carries no boxed warning. Its warnings include bone marrow suppression with reported deaths, higher in people with liver disease; liver enzyme elevations in about 16 percent of trial patients; retinal damage when eye lesions are present in neurocysticercosis; and seizures or headache as brain lesions respond. Albendazole can harm a fetus: a pregnancy test is required before starting, and MedlinePlus advises avoiding pregnancy during treatment and for 3 days after the last dose. Dexamethasone, praziquantel and cimetidine raise its levels; phenytoin, carbamazepine and phenobarbital lower them. People allergic to benzimidazoles, including mebendazole, should not take it. A drugs.com breastfeeding review reports only small amounts reach milk and a single dose is considered compatible with nursing. For stomach pain, nausea, headache or hair thinning, talk to your prescriber or pharmacist; seek care right away for fever, sore throat, unusual bruising or bleeding, or rash.
Albendazole is a prodrug. Oral absorption is limited by low aqueous solubility, first-pass sulfoxidation leaves negligible parent drug in plasma, and a fatty meal raises albendazole sulfoxide concentrations up to about fivefold, so the label recommends administration with food; for intraluminal infections, StatPearls notes an empty stomach is often used instead. Albendazole sulfoxide is about 70 percent protein bound, widely distributed including into cyst fluid and CSF, with a terminal half-life of 8 to 12 hours; elimination is largely biliary. Labeled indications for Albenza tablets: parenchymal neurocysticercosis due to active Taenia solium lesions, and cystic hydatid disease of the liver, lung and peritoneum due to Echinococcus granulosus. Prescribers have ordered compounded albendazole suspension for pinworm, hookworm, ascariasis, trichuriasis, strongyloidiasis, trichinosis, filariasis and metronidazole-resistant giardiasis, uses StatPearls lists beyond the two FDA-approved indications. Dosing and course length are per prescriber. Monitoring: CBC with differential and transaminases at the start of each 28-day cycle and every 2 weeks during therapy, with discontinuation considered if liver enzymes exceed twice the upper limit of normal; pregnancy test before therapy; retinal examination before treating neurocysticercosis; theophylline levels when co-administered. CYP inducers can lower exposure by up to half. Not a controlled substance.
Shake the bottle if your label says to. Measure each dose with the oral syringe or dosing cup the pharmacy gave you, never a kitchen spoon. Give the liquid slowly into the mouth. Rinse the syringe with water after each use. Call the pharmacy if you are unsure how to measure.
Storage depends on the vehicle. Water-based liquids with a preservative usually carry a USP <795> beyond-use date of up to 35 days; without a preservative they are kept refrigerated for up to 14 days. Oil-based (nonaqueous) oral liquids may carry up to 90 days. Your label states whether to refrigerate and the beyond-use date. Keep out of reach of children and discard after that date.
This formulation is compounded by Bayview Pharmacy on a prescriber's order for an individual patient. It is not an FDA-approved drug product, and the FDA has not evaluated it for safety, effectiveness, or manufacturing quality.
A valid prescription is required. Availability depends on Bayview's licensure in your state. This page is general information, not medical advice. Discuss your situation with a licensed healthcare provider.
Search by NCPDP 4106882, or by name and ZIP: Bayview Pharmacy, Warwick, RI 02886. Select it as the destination pharmacy and save it as a favorite. Click any value to copy it.
Compounded preparations have no NDC, so this formula will not appear in your EHR's drug search. Use your system's compound, non-formulary, or free-text prescription entry and name the preparation exactly as written in step 3. If your EHR forces you to pick a listed drug, pick the closest entry for the active ingredient and put the full formula in the prescription body (the Sig or directions field), not in Notes to Pharmacy.
Compounded preparations have no NDC and will not appear in your drug search. For EPCS to validate, select a drug entry your EHR recognizes as controlled, usually the bulk powder entry for the active ingredient (for example Ketamine (bulk) powder, not a branded product), then put the full formula from step 3 in the prescription body. A free-text entry that does not validate as controlled will be rejected by your EPCS module.
Quantity and directions are starting points for this dose form, not treatment recommendations. Dosing remains the prescriber's responsibility.
Transmit from your EHR. For this non-controlled preparation we also accept fax to (401) 284-4506 and phoned orders at (401) 284-4505. Order forms are on the formulation pages and in the prescriber portal.
Transmit with two-factor authentication through your EPCS-enabled EHR. No order form is offered for this preparation; e-prescribing guides for our controlled preparations are on the formulation pages.
Licensed to dispense in RI, MA, CT, NJ, NH, FL, ME, and PA; New York is served on a limited basis while nonresident registration is pending. Compounded preparations are not FDA-approved. A valid prescription is required. Full guide, including steps by EHR: How to e-prescribe to Bayview. Questions about this formula: call (401) 284-4505.
Take orally